Idorsia's TRYVIO Receives FDA Approval as First-in-Class ERA for Resistant Hypertension
FDA Approval and Mechanism of Action
On March 19, 2024, the U.S. FDA approved Idorsia's TRYVIO (aprositentan) for the treatment of uncontrolled, resistant hypertension in adults, to be used in combination with other medications. This once-daily medication is a dual endothelin receptor antagonist (ERA) that simultaneously blocks endothelin A and B receptors, reducing vasoconstriction and signals for sodium and water retention. It is a commercially approved product following the FDA approval process, and its clinical differentiation lies in targeting a pathway distinct from the conventional renin-angiotensin-aldosterone system (RAAS)-centered treatments.
Clinical Evidence and Safety
The approval is based on the PRECISION study (NCT03541174), a randomized, phase 3 trial involving 730 patients across 20 countries. At week 4, the mean change in systolic blood pressure from baseline in the aprositan 12.5mg group was -15.3 mmHg, with a placebo-corrected difference of -3.8 mmHg, which met statistical significance. The 40-week discontinuation trial showed that the systolic blood pressure in the placebo group increased by 5.8 mmHg compared to the continued treatment group, supporting the sustained efficacy. However, fluid retention/edema, anemia, hepatotoxicity, and embryofetal toxicity are key safety variables that may limit broader prescribing.
Regulatory History and Commercial Implications
The FDA has formally approved NDA 217686, and the public review history indicates that no advisory committee (AdComm) vote was held. In Europe, the product, marketed as JERAYGO, received a positive CHMP opinion on April 25, 2024, and obtained marketing authorization from the European Union on June 27, 2024. There is no record of approval by the Japanese PMDA. The approved dose in the U.S. is 12.5mg once daily, while in Europe, the dose can be increased from 12.5mg to 25mg based on tolerability and the need for additional blood pressure control, resulting in different regional commercial strategies.
Market and Competitive Landscape
The global antihypertensive drug market is approximately USD 23.9 billion in 2024, and the current standard of care for resistant hypertension is the low-cost generic mineralocorticoid receptor antagonist, spironolactone. TRYVIO has secured a novel mechanism and approval status, but the approval of AstraZeneca's (AZN) aldosterone synthase inhibitor, baxdrostat (Baxfendy), in May 2026, will intensify competition among new mechanisms. Mineralys Therapeutics' (MLYS) rolnedostat is also in the FDA review stage after completing phase 3 trials, and TRYVIO's market share will depend on real-world prescription persistence, edema management, insurance coverage, and blood pressure reduction compared to competing drugs.
The approval of TRYVIO provides a first-in-class endothelin receptor antagonist option for patients with uncontrolled hypertension despite treatment with three or more medications, and it transitions Idorsia's cardiovascular assets from a development-stage to a revenue-generating stage. In the phase 3 PRECISION trial, the placebo-corrected reduction in systolic blood pressure was 3.8 mmHg at week 4 and 5.8 mmHg in the 40-week discontinuation trial with 12.5mg, but monitoring for fluid retention and anemia will determine the speed of market penetration. In the USD 23.9 billion antihypertensive market, low-cost spironolactone is established as the standard fourth-line treatment, creating price and reimbursement barriers. In the medium to long term, Baxfendy, which has been approved by the FDA, and rolnedostat, which is in the FDA review process, will compete directly, and comparisons of efficacy and safety between ERAs and aldosterone synthase inhibitors will be key criteria for research and development and capital allocation.
Source: openFDA (api_fda)
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=NDA217686